SuperCitizen

The federal Right to Try Act (2018) and parallel state laws allow terminally ill patients to request access to investigational drugs that have completed Phase I clinical trials but have not received full FDA approval. The law operates outside the FDA's pre-existing Expanded Access ("compassionate use") program.

Supporters frame these laws as restoring patient autonomy in life-or-death situations. Critics argue the laws bypass safety review, may give false hope, and do little that Expanded Access did not already do — while shielding drug companies from liability.

In practice, manufacturers retain discretion over whether to provide the drugs, so access remains limited. The debate continues over whether right-to-try expanded real access or primarily served symbolic and political ends.

Spectrum of framings

How adherents on each side of the conventional left / center / right spectrum frame this issue — written so each camp would recognize the framing as charitable.

left

Progressives are often skeptical, worrying that right-to-try bypasses essential safety review, exploits vulnerable patients, and weakens FDA authority.

center

Centrists often see right-to-try as a modest expansion of existing compassionate-use pathways, with limited practical effect beyond signaling.

right

Conservatives and libertarians frame right-to-try as a fundamental autonomy issue: dying patients should not need government permission to try treatments their doctors recommend.

Perspectives

Each perspective is presented in terms its advocates would recognize, with the concerns they treat as paramount. None is endorsed.

Patient autonomy advocates

A dying patient has nothing to lose from trying an experimental treatment. Government has no legitimate authority to stand between a terminal patient and a possible therapy their doctor believes could help.

Patient self-determination at end of life
Bypassing bureaucratic delays
Hope and dignity for terminal patients

FDA-process defenders

Phase I trials only establish basic safety, not efficacy. Right-to-try can expose patients to ineffective or harmful drugs, generate misleading anecdotes, and undermine the trials that establish whether treatments actually work.

Phase II/III efficacy data still missing
Risk of exploitation and false hope
Distortion of clinical trial enrollment

Pragmatic skeptics

Right-to-try largely duplicates the FDA Expanded Access program, which already approves the vast majority of compassionate-use requests. Practical access is limited by manufacturer willingness, not federal rules.

Redundancy with Expanded Access
Manufacturer discretion as real bottleneck
Symbolic vs. practical impact